Diana Pacheco Sousa

Diana Pacheco Sousa

Auto-generated profile, based on publicly available information

Diana Pacheco Sousa

NOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Journal of the American Chemical Society
Verified
Journal Article
Open access
XCXu Chen
Xu Chen
BMBárbara B. Mendes
Bárbara B. Mendes
YZYunhui Zhuang
Yunhui Zhuang
JCJoão Conniot
João Conniot
SASergio Mercado Argandona
Sergio Mercado Argandona
DFDavid Fairen-Jimenez
David Fairen-Jimenez
Photodynamic therapy (PDT), an emergent noninvasive cancer treatment, is largely dependent on the presence of efficient photosensitizers (PSs) and a sufficient oxygen supply. However, the therapeutic efficacy of PSs is greatly compromised by poor solubility, aggregation tendency, and oxygen depletion within solid tumors during PDT in hypoxic microenvironments. Despite the potential of PS-based metal-organic frameworks (MOFs), addressing hypoxia remains challenging. Boron dipyrromethene (BODIPY) chromophores, with excellent photostability, have exhibited great potential in PDT and bioimaging. However, their practical application suffers from limited chemical stability under harsh MOF synthesis conditions. Herein, we report the synthesis of the first example of a Zr-based MOF, namely, 69-L2, exclusively constructed from the BODIPY-derived ligands via a single-crystal to single-crystal post-synthetic exchange, where a direct solvothermal method is not applicable. To increase the PDT performance in hypoxia, we modify 69-L2 with fluorinated phosphate-functionalized methoxy poly(ethylene glycol). The resulting 69-L2@F is an oxygen carrier, enabling tumor oxygenation and simultaneously acting as a PS for reactive oxygen species (ROS) generation under LED irradiation. We demonstrate that 69-L2@F has an enhanced PDT effect in triple-negative breast cancer MDA-MB-231 cells under both normoxia and hypoxia. Following positive results, we evaluated the in vivo activity of 69-L2@F with a hydrogel, enabling local therapy in a triple-negative breast cancer mice model and achieving exceptional antitumor efficacy in only 2 days. We envision BODIPY-based Zr-MOFs to provide a solution for hypoxia relief and maximize efficacy during in vivo PDT, offering new insights into the design of promising MOF-based PSs for hypoxic tumors.

15 May 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
BMBárbara B. Mendes
Bárbara B. Mendes
ZZZilu Zhang
Zilu Zhang
JCJoão Conniot
João Conniot
DSDiana P. Sousa
Diana P. Sousa
JRJoão M. J. M. Ravasco
João M. J. M. Ravasco
JCJoao Conde
Joao Conde

1 September 2021 in Trends in Cancer
Verified
Journal Article
Closed access
BMBárbara B. Mendes
Bárbara B. Mendes
DSDiana P. Sousa
Diana P. Sousa
JCJoão Conniot
João Conniot
JCJoao Conde
Joao Conde

15 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LLLiliana R. Loureiro
Liliana R. Loureiro
DSDiana P. Sousa
Diana P. Sousa
DFDylan Ferreira
Dylan Ferreira
WCWengang Chai
Wengang Chai
IPO-Porto LimaIPO-Porto Lima
IPO-Porto Lima
PVPaula Videira
Paula Videira
Incomplete O-glycosylation is a feature associated with malignancy resulting in the expression of truncated glycans such as the sialyl-Tn (STn) antigen. Despite all the progress in the development of potential anti-cancer antibodies, their application is frequently hindered by low specificities and cross-reactivity. In this study, a novel anti-STn monoclonal antibody named L2A5 was developed by hybridoma technology. Flow cytometry analysis showed that L2A5 specifically binds to sialylated structures on the cell surface of STn-expressing breast and bladder cancer cell lines. Moreover, immunoblotting assays demonstrated reactivity to tumour-associated O-glycosylated proteins, such as MUC1. Tumour recognition was further observed using immunohistochemistry assays, which demonstrated a high sensitivity and specificity of L2A5 mAb towards cancer tissue, using bladder and colorectal cancer tissues. L2A5 staining was exclusively tumoural, with a remarkable reactivity in invasive and metastasis sites, not detectable by other anti-STn mAbs. Additionally, it stained 20% of cases of triple-negative breast cancers, suggesting application in diseases with unmet clinical needs. Finally, the fine specificity was assessed using glycan microarrays, demonstrating a highly specific binding of L2A5 to core STn antigens and additional ability to bind 2–6-linked sialyl core-1 probes. In conclusion, this study describes a novel anti-STn antibody with a unique binding specificity that can be applied for cancer diagnostic and future development of new antibody-based therapeutic applications.

13 August 2022 in ACS Materials Au
Verified
Journal Article
Open access
DSDiana P. Sousa
Diana P. Sousa
JCJoao Conde
Joao Conde
Cancer is a major healthcare burden and cause of death worldwide, with an estimated 19.3 million new cancer cases and 10 million cancer deaths globally only in 2020. While several anticancer therapeutics are available to date, many of these still show low treatment efficacy and high off-target effects and adverse reactions. This prompts a serious need to develop novel therapies that can decrease the side effects and increase treatment efficacy. MicroRNAs (miRNAs) can have a role in tumor development and progression, making them important targets for the improvement of anticancer therapies. In this context, gold nanoparticles have been widely studied for different clinical applications due to their biocompatibility and possibility of customization, and gold nanoconjugates targeting miRNAs are being developed for cancer diagnosis and treatment. Here we summarize the research developed so far and how it can contribute to cancer treatment, discuss how it can be improved, and present the current challenges and future perspectives on their design and application.

9 July 2019 in Nutrition and Cancer
Verified
Journal Article
Closed access
DSDiana P. Sousa
Diana P. Sousa
MPMarta Pojo
Marta Pojo
APAna Teresa Pinto
Ana Teresa Pinto
VLValeriano Leite
Valeriano Leite
ASAna Teresa Serra
Ana Teresa Serra
BCBranca Maria Cavaco
Branca Maria Cavaco
Aim: Anaplastic thyroid cancer (ATC) is the most aggressive subtype of thyroid cancer, presenting high mortality. Currently, no curative treatments exist and new therapeutic strategies are required. Although nutraceuticals were reported to have anticancer properties, few studies exist on ATC. This study aimed to investigate the anticancer effects of nutraceuticals in ATC cell lines (T235, T238) in comparison with normal thyroid cells (PCCL3). Methods: The IC50 values of isothiocyanates (ITCs: sulforaphane, SFN; phenethyl isothiocyanate, PEITC) and polymethoxylated flavones (PMFs: nobiletin; orange peel extract, OPE) were determined. ITCs decreased ATC metabolic viability more efficiently than PMFs. The effects of PEITC and nobiletin on viability and cell cycle, alone or in combination with conventional drugs, were evaluated. Results: PEITC did not affect viability of normal thyroid and ATC cells, while nobiletin decreased viability in a dose-dependent manner in all cell lines, although cell cycle was not arrested. At 100 μM, nobiletin reduced ATC cell viability as efficiently as conventional drugs, such as cisplatin, while being less toxic to normal thyroid cells. When conjugated with 1 μM cisplatin, the combination decreased viability of T235 cells more efficiently than each compound alone. Conclusion: These results suggest nobiletin as a potential anticancer agent that warrants further investigation in ATC.